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Abstract: The cytoprotective effects of erythropoietin (EPO) and an EPO-related nonery-
thropoietic analog, pyroglutamate helix B surface peptide (pHBSP), were investigated in an in 
vitro model of bovine aortic endothelial cell injury under normoxic (21% O
2
) and hypoxic (1% 
O
2
) conditions. The potential molecular mechanisms of these effects were also explored. Using 
a model of endothelial injury (the scratch assay), we found that, under hypoxic conditions, 
EPO and pHBSP enhanced scratch closure by promoting cell migration and proliferation, but 
did not show any effect under normoxic conditions. Furthermore, EPO protected bovine aortic 
endothelial cells from staurosporine-induced apoptosis under hypoxic conditions. The priming 
effect of hypoxia was associated with stabilization of hypoxia inducible factor-1α, EPO recep-
tor upregulation, and decreased Ser-1177 phosphorylation of endothelial nitric oxide synthase 
(NOS); the effect of hypoxia on the latter was rescued by EPO. Hypoxia was associated with 
a reduction in nitric oxide (NO) production as assessed by its oxidation products, nitrite and 
nitrate, consistent with the oxygen requirement for endogenous production of NO by endothelial 
NOS. However, while EPO did not affect NO formation in normoxia, it markedly increased 
NO production, in a manner sensitive to NOS inhibition, under hypoxic conditions. These data 
are consistent with the notion that the tissue-protective actions of EPO-related cytokines in 
pathophysiological settings associated with poor oxygenation are mediated by NO. These find-
ings may be particularly relevant to atherogenesis and postangioplasty restenosis.
Keywords: erythropoietin, pyroglutamate helix B surface peptide, scratch assay, proliferation, 
migration, apoptosis
Introduction
Inflammation and hypoxia are often associated with tissue injury and are involved in 
wound repair and atherogenesis.1,2 We have previously reported that the reparative effects 
of erythropoietin (EPO) on endothelial cells is more evident under 5% oxygen (O
2
) 
compared to atmospheric oxygen concentrations (21%).3 However, 5% O
2
 is close to 
physiological tissue oxygen concentrations, while persistent, more severe hypoxia (,1% 
O
2
), such as following ischemia, can be deleterious and is associated with endothelial 
injury due to effects on a variety of cellular processes.4 Hypoxia induces the expression 
of several cytokines such as vascular endothelial growth factor (VEGF) and EPO, which, 
in turn, help orchestrate the chronic adaptation to hypoxia. While the principal effect 
of EPO is to increase the number of red blood cells and thus improve oxygenation, it is 
also tissue protective and prevents ischemic injury of the vascular endothelium.5–7 These 
protective effects of EPO may be mediated in part by its stimulation of endothelial cell 
proliferation and migration (in cases of endothelial damage), inhibition of apoptosis 
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and inflammation, and induction of angiogenesis.8–10 These 
effects are mediated by a tissue-protective receptor, which 
is distinct from the canonical homodimeric EPO receptor 
(EPOR) mediating its erythropoietic effects, and comprises a 
heterodimeric complex composed of EPOR and the common 
β-subunit of receptors for granulocyte-macrophage colony-
stimulating factor, interleukin-3, and interleukin-5 (βCR, also 
known as CD131).
Nonerythropoietic analogs of EPO that are tissue protec-
tive but not erythropoietic may represent a potentially safer 
and more effective intervention for the treatment of vascular 
disease, as they lack the erythropoietic properties of EPO that 
may lead to some of its adverse vascular complications.5,11,12 
EPO and its nonerythropoietic analogs have been shown to 
promote wound healing13,14 and confer protection in models 
of cardiovascular injury.15,16 We have previously shown that 
these nonerythropoietic analogs (carbamylated EPO and 
the synthetic peptide pyroglutamate helix B surface peptide 
[pHBSP]) exhibit tissue-protective effects that are similar to 
EPO in an in vitro vascular cell injury model at a low oxygen 
tension (5% O
2
) but not in normoxia.3 The aim of the present 
investigation was to study the potentially protective effects 
of EPO and its novel nonerythropoietic analog pHBSP under 
conditions in which the hypoxia was more pronounced (1% 
O
2
) and to determine the putative molecular mechanisms by 
which these two entities confer protection. For this purpose, 
we used an in vitro model of wound healing (the “scratch 
assay”) in bovine aortic endothelial cells (BAECs). The effects 
of EPO and pHBSP on cellular migration, proliferation, and 
apoptosis were studied and related to the formation of nitric 
oxide (NO) by measuring NO production and testing the effect 
of specific enzyme inhibitors and NO scavengers.
Materials and methods
All chemicals were from Sigma-Aldrich Co. (St Louis, MO, 
USA), unless otherwise stated. The peptide (pHBSP, or 
ARA290; pyroglu-EQLERALNSS) and the scrambled peptide 
(scr-pHBSP; pyroglu-LSEARNQSEL) used as a control peptide 
for our experiments were provided by Araim Pharmaceuticals 
(Tarrytown, NY, USA). Typically, 100× stock solutions were 
prepared fresh in phosphate-buffered saline (PBS) and sterile-
filtered before addition to cells; 2-phenyl-4,4,5,5-tetramethylim-
idazoline-1-oxyl 3-oxide (PTIO) and staurosporine were kept 
frozen as 1,000× aliquots in dimethyl sulfoxide.
Cell culture
BAECs were obtained from European Collection of Authen-
ticated Cell Cultures (ECACC) (Salisbury, UK) and used 
between passages 4 and 12. The cells were cultured in 
Dulbecco’s Modified Eagle’s medium supplemented with 
10% fetal bovine serum and penicillin/streptomycin (final 
concentration 100 IU/mL) and were cultured, prior to our 
experiments, at 37°C in a humidified atmosphere contain-
ing 5% CO
2
 and 21% O
2
 (corresponding to an effective O
2
 
concentration of 18.6%).17 When indicated, hypoxic experi-
ments were performed under 1% O
2
, 5% CO
2
, and 94% N
2
 
in an acrylic chamber where O
2
 was maintained at such a 
low level using a CO
2
 and O
2
 controller (ProOx model c21, 
BioSpherix, Ltd, New York, USA).
Scratch assay
The scratch assay was performed as previously described.3 The 
effects of EPO, its peptide analog (pHBSP), or a scrambled 
peptide (scr-pHBSP) as a control were investigated in either 
21% or 1% O
2
. A reproducible scratch was produced in the 
endothelial monolayer as previously described, and thereafter, 
either EPO or pHBSP or scr-pHBSP was added to the cells 
and subsequently incubated in a 21% or 1% O
2
 for 24 hours. 
Optimal concentrations for each agonist were established in 
earlier experiments (Figure S1A).3 The defined area of the 
scratch was photographed under an inverted microscope 
(Olympus CKX41; Olympus Corporation, Tokyo, Japan) 
at 10× magnification using a Micropix 5 megapixel color 
complementary metal-oxide semiconductor digital camera 
(Olympus Cooperation). The position of the wound image 
was standardized each time against a horizontal line drawn 
on the base of the plate passing through the center of each 
well. The scratch area was quantified using ImageJ software 
(National Institutes of Health, Bethesda, MD, USA).
In some experiments, either the nitric oxide synthase 
(NOS) inhibitor NG-nitro-l-arginine methyl ester (l-NAME; 
300 µM) or l-NG-monomethyl-l-arginine (l-NMMA; 1 mM) 
was added 30 minutes prior to the addition of EPO. To test 
whether the effect observed was NO dependent regardless of 
its source, the NO scavenger PTIO (150 µM) was used and 
added 30 minutes prior to addition of EPO. l-NAME was 
freshly prepared for each experiment, while l-NMMA and 
PTIO were used from frozen stock solutions.
Cell viability assay
Cell viability was evaluated using the trypan blue exclusion 
test as previously described.3 Briefly, cells were seeded into 
96-well plates at a density of 1×104 cells/mL (0.15 mL/
well) in culture medium. After 24 hours, the supernatant was 
removed and replaced by 150 µL fresh medium containing 
EPO, pHBSP, or scr-pHBSP at a concentration of 1 ng/mL, 
122
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and the cells were incubated at 21% or 1% O
2
. After 24 hours, 
trypan blue was added and the cells that were stained (dead) 
and unstained (live) were counted. Results were expressed 
as viable cell count per milliliter. To test whether the effects 
of EPO or its analog were mediated by NO, in some experi-
ments, we used the NOS inhibitor l-NAME (300 µM).
Migration assay
A micro-Boyden chamber assay (NeuroProbe, Gaithersburg, 
MD, USA) was used to assess the effect of 1 ng/mL EPO, 
pHBSP, and scr-pHBSP on cell migration.18 Migrated cells 
were stained using Diff-Quick stain (Gamidor Technical 
Services Ltd, Didcot, UK) and counted under 40× magni-
fication. To investigate whether the effects of EPO and its 
analog were mediated by endothelial NOS (eNOS). Some 
experiments were performed in the presence of 300 µM of 
the NOS inhibitor l-NAME.
Apoptosis
Caspase-3 activity measurement assay
Caspase-3/7 activity was measured using the Caspase-Glo 
3/7 assay (Promega Corporation, Fitchburg, WI, USA). 
Cells were plated into 96-well plates at a seeding density 
of 5×104 cell/mL and cultured for 24 hours in 1% or 21% 
O
2
. Cells were then treated with either EPO (1 ng/mL) or 
vehicle (medium) for 3 hours, before apoptosis was induced 
by adding 500 nM staurosporine for 18 hours. Reconstituted 
Caspase-Glo 3/7 reagent was added to each well at a volume 
equal to that of the cell culture media (100 µL caspase-Glo 
reagent to 100 µL cell culture medium). Plates were mixed 
gently using a plate shaker at 300–500 rpm for 30 seconds 
and incubated at room temperature for 1 hour; 100 µL of 
each well was then transferred to a Corning Costar 96-well 
White Solid Plate (Thermo Fisher Scientific, Waltham, MA, 
USA) and luminescence was measured using a Synergy HTX 
plate reader (BioTek, Swindon, UK).
Deadend colorimetric TUNel assay
Terminal deoxynucleotidyl transferase dUTP (2’-deoxyuri-
dine 5’-triphosphate) nick end labeling (TUNEL) assay was 
also used to measure cell apoptosis. BAECs were cultured on 
poly l-ornithine coated cover slips until reaching confluence. 
Cells were then cultured under 21% or 1% O
2
 for 24 hours 
prior to treatment with EPO and staurosporine as described 
earlier. Thereafter, cells were washed with PBS and fixed with 
4% paraformaldehyde for 15 minutes at room temperature. 
Fixed cells were then washed with PBS and treated with 1% 
Triton X-100 in PBS (Sigma-Aldrich Co.) for 10 minutes at 
room temperature to permeabilize the plasma membrane. The 
proportion of apoptotic cells was then detected in the fixed 
permeabilized cells following a standard protocol (Promega 
Corporation).19 A light microscope (40× magnification) was 
used to quantify the staining.
Real-time quantitative polymerase chain 
reaction (qPCR)
Cells were seeded into 24-well plates and cultured until 
~80% confluent and were then exposed to 1% or 21% O
2
 
for 24 hours. The effect of 1 ng/mL EPO on gene expres-
sion was assessed at several time points (0, 0.5, 1, and 24 
hours). Cells were then lysed using TRIzol (Thermo Fisher 
Scientific), and RNA was extracted and purified as described 
previously.20 RNA quality and concentration were deter-
mined using NanoDrop ND-1000 (NanoDrop Technologies, 
Thermo Fisher Scientific, Waltham, MA, USA).20 Reverse 
transcription and real-time qPCR for EPOR, βCR, VEGF, 
and β2-microglobulin (a housekeeping gene not affected by 
changes in O
2
 levels) were carried out on RNA samples using 
Taqman gene expression assays (Thermo Fisher Scientific) 
as previously reported.20,21 For gene expression quantifica-
tion, the comparative threshold cycle (∆∆Ct) method was 
used following the guidelines of Thermo Fisher Scientific. 
Results were normalized to β2-microglobulin expression 
and expressed as arbitrary units using one of the normoxic 
samples as a calibrator as specified in the figure legend 
(Figure 4). VEGF, a hypoxia-induced gene, was measured 
as a positive control to validate the method and conditions 
used for the experiment.
Western blot
BAECs were seeded into 24-well plates at a seeding den-
sity of 1×105 cell/mL and cultured until 80% confluency, 
and were then exposed for a further 24 hours under 1% or 
21% O
2
. Cells were then lysed and their protein quantified 
as previously described.3 Thirty micrograms of cellular 
proteins was separated on 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred onto 
a nitrocellulose membrane (GE Healthcare UK Ltd, Little 
Chalfont, UK). After blocking with 5% skimmed milk (for 
EPOR and hypoxia inducible factor-1α [HIF-1α] detection) 
or 5% bovine serum albumin (for βCR, phosphorylated 
eNOS [p-eNOS], and Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) detection) for 1 hour, the membranes were 
incubated with the appropriate primary antibody overnight, 
followed by horseradish peroxidase-conjugated secondary 
antibodies for 1 hour at room temperature. βCR, p-eNOS, 
123
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and GAPDH (loading control) were detected using rabbit 
anti-βCR (N-20; Santa Cruz Biotechnology Inc., Dallas, 
TX, USA), rabbit anti-p-eNOS (9571S; New England 
Biolabs Ltd, UK), and rabbit anti-GAPDH (14C10; New 
England Biolabs Ltd, Hertfordshire, UK) at a dilution of 
1:200, 1:2,000, and 1:1,000, respectively, and an antirabbit 
secondary antibody (A0545; Sigma-Aldrich Co.) at 1:5,000 
dilution for βCR and 1:20,000 dilution for p-eNOS and 
GAPDH. EPOR was detected using goat anti-EPOR (W-20; 
Santa Cruz Biotechnology Inc.) at 1:200 dilution and an 
anti-goat secondary antibody (A8919, Sigma-Aldrich Co.) 
at 1:10,000 dilution. HIF-1α was detected using mouse anti-
HIF-1α (NB 100-105, R&D systems, Abingdon, UK) at 
1:500 dilution and an antimouse secondary antibody (ADI-
SAB-100; Enzo Life Sciences Ltd, Exeter, UK) at 1:5,000 
dilution. Protein bands were visualized by exposing the 
membranes developed with the Enhanced Chemilumines-
cence (ECL) reagent to chemiluminescence film (Hyperfilm 
ECL, GE Healthcare UK Ltd). Bands were quantified using 
ImageJ software (National Institutes of Health).
Measurement of NO
NO production in BAECs was quantitatively measured in 
the form of its stable oxidation products, nitrite (NO
2
−) and 
nitrate (NO
3
−), as previously described.22 Briefly, BAECs 
were seeded in six-well plates at a seeding density of 1×106 
cells/mL. Cells were then either left untreated or treated 
with 1 ng/mL EPO, 1 mM l-NMMA, or a combination of 
EPO and l-NMMA and incubated at either 1% or 21% O
2
. 
After 24 hours, the cell culture medium was collected, snap 
frozen in liquid N
2
, and stored at −80°C for later analysis of 
extracellular nitrite and nitrate release, replace by; a measure 
of NOS activity. In addition, intracellular nitrite and nitrate 
levels were measured as follows. After removal of the super-
natant, the treated BAECs were washed twice with PBS to 
minimize contamination with extracellular nitrite/nitrate 
and subjected to three successive freeze/thaw cycles in the 
presence of a limited volume (250 µL) of PBS. The fractured 
cells and cell lysates from each well were collected using a 
rubber policeman, quantitatively transferred to a prewashed 
Eppendorf vial, followed by methanol precipitation (1:1 v/v) 
of proteins and centrifugation at 11,000 ×g. The supernatant 
was transferred to a prewashed cryovial, snap frozen, and 
stored at −80°C for up to 1 week before analysis. Nitrite 
and nitrate were quantified simultaneously using a specific 
and sensitive high-performance liquid chromatography 
technique that employs ion chromatography with online 
reduction of nitrate to nitrite and subsequent postcolumn 
derivatization with Griess reagent (ENO-20; EiCom, Kyoto, 
Japan).22 Calibration curves for nitrite and nitrate standards 
(0.01–50 µM in PBS) were constructed daily, and an internal 
quality control was run after every ten samples; using a 20 µL 
injection loop, the detection limit was 25 nM for each anion. 
Cell culture medium without the cells being treated under 
otherwise identical conditions or PBS served as control. All 
values reported are corrected for the corresponding blanks.
Statistical analysis
All data were analyzed using GraphPad Prism 4 software 
(GraphPad Software, Inc., La Jolla, CA, USA). Differences 
in treatment (with or without EPO or its analogs) were tested 
for significance using one-way analysis of variance followed 
by a Bonferroni correction for multiple comparisons post hoc 
test. The t-test was used to compare the expression of EPOR 
or βCR under different O
2
 levels.
Results
Hypoxia stimulates reparative effects of 
EPO and its analogs
As shown in Figure 1A, EPO and pHBSP significantly 
enhanced scratch closure, 24 hours after treatment, in BAECs 
cultured under conditions of acute hypoxia (1% O
2
). However, 
EPO and its peptide analog did not significantly improve 
wound closure in cells maintained in 21% O
2
. No significant 
effect was observed after treatment with the scrambled pep-
tide (scr-pHBSP) under either 21% or 1% O
2
.
The eNOS inhibitor, l-NAME was used at the concentra-
tion giving optimum inhibition as verified by a concentration 
response curve on wound closure (300 µM) (Figure S1B). 
l-NAME inhibited wound closure significantly when added 
to endothelial cells kept at 21% O
2
 but showed no effect on 
untreated cells under 1% O
2
. l-NAME also inhibited wound 
closure in the presence of concomitant treatment with EPO 
or pHBSP at both 21% O
2
 and 1% O
2
 (Figure 1B).
EPO and pHBSP induce proliferation 
and migration of BAECs under hypoxic 
conditions
EPO and pHBSP had little effect on cell proliferation at 
21% O
2
 but stimulated proliferation to a comparable extent 
in hypoxia (Figure 2A). Treatment with scr-pHBSP did 
not affect proliferation under either 21% or 1% O
2
. NOS 
inhibition by l-NAME had a significant inhibitory effect on 
proliferation of BAECs under 21% O
2
 (Figure 2B), but this 
effect was not observed under 1% O
2
. The EPO-induced 
enhancement of cell proliferation in hypoxia was completely 
inhibited by l-NAME (Figure 2B). Similar findings were 
observed on cell migration (Figure 2C and D).
124
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Antiapoptotic effect of EPO is stimulated 
under hypoxic conditions
To investigate the potential antiapoptotic effects of EPO 
and its nonerythropoietic analog, apoptosis was induced 
by exposing BAECs to 500 nM staurosporine for 18 hours. 
Both EPO and pHBSP had a significant antiapoptotic 
effect under 1% O
2
, but not under 21% O
2.
 EPO inhibited 
staurosporine-induced apoptosis by approximately 50% 
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Figure 1 EPO and pHBSP stimulate repair in a scratch assay model in BAEC under hypoxia.
Notes: (A) EPO and pHBSP (1 ng/mL each) enhanced wound closure in BAECs when incubated in 1% O2 for 24 hours, but not under 21% O2 (**P,0.01 for EPO and pHBSP 
treated cells versus untreated cells). The scrambled peptide control (scr-pHBsP) had no significant effect on wound closure in Baecs under either 21% or 1% O2. (B)The 
NOs inhibitor; l-NaMe (300 µM) decreased wound closure for untreated cells under 21% O2 (*** P,0.001), but showed no significant effect under 1% O2. l-NaMe (300 µM) 
inhibited wound closure in EPO or pHBSP treated cells under both 21% and 1% O2 (* P,0.05 for EPO and pHBSP treated cells in presence versus absence of l-NaMe). 
Results are expressed as % wound healing after 24 hours. Each data point represents the mean value ± SEM (n=6). statistical analysis was carried out using one-way aNOVa 
followed by Bonferroni posthoc test.
Abbreviations: Baec, bovine aortic endothelial cell; ePO, erythropoietin; l-NaMe, Ng-nitro-l-arginine methyl ester; pHBsP, pyroglutamate helix B surface peptide; scr-
pHBsP, scrambled pHBsP; seM, standard error of the mean.
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Figure 2 EPO and pHBSP stimulate proliferation and migration of BAECs under hypoxia. BAECs were treated with EPO, pHBSP, and scr-pHBSP at 1 ng/mL and were then 
incubated under either 21% or 1% O2 for 24 hours.
Notes: The effects of EPO, pHBSP, and scr-pHBSP, as well as the effect of l-NaMe (300 µM) in the presence and absence of EPO on proliferation of BAECs were analyzed 
by cell counting using the trypan blue exclusion assay (A and B) and on migration of BAECs using a micro-Boyden chamber chemotactic assay (C and D). EPO and pHBSP 
(1 ng/mL each) enhanced proliferation (*P,0.05) and migration (***P,0.001) in BAECs when incubated in 1% O2 for 24 hours, but not under 21% O2. l-NaMe (300 µM) 
inhibited proliferation and migration in EPO treated cells (*P,0.05). Each data point represents mean ± SEM (n=3). statistical analysis was carried out using one-way aNOVa 
followed by Bonferroni posthoc test.
Abbreviations: Baec, bovine aortic endothelial cell; ePO, erythropoietin; l-NaMe, NG-nitro-l-arginine methyl ester; pHBsP, pyroglutamate helix B surface peptide; scr-
pHBsP, scrambled pHBsP; seM, standard error of the mean.
125
Hypoxia enhances tissue-protective effect of erythropoietin
 
H
yp
ox
ia
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
18
4.
17
1.
18
2 
on
 0
6-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Hypoxia 2016:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
on using either the TUNEL (Figure 3A and B) or caspase 
assay (Figure 3C).
Hypoxia regulates different EPO-related 
downstream signaling pathways
qPCR and Western blot were used to study the effect of EPO 
on both the mRNA and protein expression, respectively, of 
selected genes and proteins. The effect of EPO on EPOR and 
βCR mRNA levels is shown in Figure 4; EPOR mRNA levels 
were significantly increased by nearly twofold in 1% O
2
. In 
contrast, the expression of βCR did not change significantly 
under the same conditions. Addition of EPO did not appear 
to affect either EPOR or βCR expression under hypoxic con-
ditions at the time points investigated. VEGF was used as a 
positive control (representative hypoxia-inducible gene) and 
was found to increase fourfold to sixfold in 1% O
2
.
We also studied some of the EPO-related signaling 
pathways that might play a role in its reparative action. For 
this purpose, we measured the protein expression of EPOR, 
βCR, HIF-1α, and p-eNOS by Western blot. Consistent 
with the mRNA measurements by PCR, EPOR expression 
was increased in 1% O
2
 compared to 21% O
2
 while the 
expression of βCR was unaltered. Expression of p-eNOS, 
on the other hand, decreased significantly under hypoxic 
conditions, but this effect was offset by treatment with 
EPO (Figure 5). Moreover, hypoxia was found to increase 
inducible NOS (iNOS) expression and EPO to suppress this 
response, but unsurprisingly, overall levels of expression 
of this NOS isoform are extremely low when compared to 
eNOS (Figure S2). Taken together, both Western blot and 
PCR showed that hypoxia affects the regulation of several 
downstream pathways. Under our experimental conditions, 
this regulation did not appear to be affected by EPO, with 
the notable exception of eNOS phosphorylation at Ser-1177. 
The latter may be of relevance in determining NO output of 
endothelial cells as phosphorylation at Ser-1177 is known 
Figure 3 Antiapoptotic effects of EPO and pHBSP under hypoxic, but not normoxic conditions. Apoptosis was induced in BAECs by treatment with 500 nM staurosporine 
for 18 hours after incubation with or without EPO or pHBSP for 3 hours.
Notes: (A) representative micrographs of the TUNel staining under 20x magnification. (B) Quantification of TUNel staining. ePO caused a decrease in apoptosis-
stimulated cells under 1% O2 (***P,0.001) but not under 21% O2 (ns, P0.05) (C) Caspase-3/7 activity where EPO and pHBSP showed anti-apoptotic effect under 1% 
O2 (*P,0.05) but not under 21% O2 (ns P0.05). Each data point represents mean ± SEM (n=3). statistical analysis was carried out using one-way aNOVa followed by 
Bonferroni posthoc test.
Abbreviations: Baec, bovine aortic endothelial cell; ePO, erythropoietin; ns, non-significant; pHBsP, pyroglutamate helix B surface peptide; seM, standard error of the 
mean; TUNel, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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to be associated with enhanced NOS activity.23 Although 
likely to be of minor importance, we cannot exclude that 
iNOS may also contribute to NO production under hypoxic 
conditions.
ePO stimulates NO production in 
hypoxia, but not in normoxia
NO production by BAECs was assessed by the formation of 
nitrate and nitrite, and both their extracellular and intracellular 
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for 0, 0.5, 1, and 24 hours.
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concentrations were determined. In general, endothelial NO 
production was significantly lower in cells incubated in 1% 
O
2
 compared to those incubated in 21% O
2
, as evidenced 
by decreases in both intracellular and extracellular nitrite 
and nitrate concentrations. In these experiments, l-NMMA 
was used as a NOS inhibitor instead of l-NAME because 
l-NAME metabolites were found to interfere with the deter-
mination of trace levels of nitrite by high-performance liquid 
chromatography and l-NMMA produced similar responses 
to l-NAME in the scratch assay (Figure S3). As shown in 
Figure 6A–D, EPO caused an increase in NO production in 
hypoxic cells compared to untreated cells. This effect was 
not observed in normoxia.
l-NMMA not only decreased basal cellular NO pro-
duction in normoxia but also partially counteracted the 
stimulatory effects of EPO on NO production in hypoxia 
(Figure 6A–D). We also tried to correlate the production 
of NO in the various experimental conditions reported in 
Figures 1, 2, and 6A–D. Association analyses reported in 
Figure 6E–H show that both cell migration and repair cor-
relate with NO production, possibly suggesting that NO is 
important for the reparative effects of EPO in this model.
To confirm this assumption, we performed additional 
experiments with the NO scavenger PTIO, which showed that, 
irrespective of its source of formation (ie, whether it is gener-
ated through a NOS-dependent or -independent pathway), NO 
is essential for the cellular wound healing process, regard-
less of the prevailing oxygen tension (Figure 7). PTIO also 
inhibited the stimulated reparative effects of EPO and pHBSP 
under hypoxic condition (Figure 7). This action of PTIO was 
not due to an effect on cell viability as confirmed using the 
trypan blue exclusion method. Cell viability in the presence 
and absence of PTIO was 89.8%±4.2% in untreated cells 
versus 87.1%±4.7% in PTIO-treated cells under normoxia 
(n=3) and 87.2%±3.4% in untreated cells versus 84.8%±9.1% 
in PTIO-treated cells under hypoxic condition (n=3).
Taken together, our findings demonstrate that hypoxia 
is an important determinant of the response to EPO and 
its analogs and that NO formation may be involved in the 
downstream signaling pathways.
Discussion
We have previously shown that EPO and its nonerythro-
poietic analogs enhance the regrowth of an endothelial 
monolayer following a scratch injury under low oxygen 
tension (5% O
2
), but not under normoxia (21% O
2
). The 
partial pressure of oxygen varies within the normal artery 
wall, even in health,24 and areas of profound hypoxia (,1% 
O
2
) may prevail in regions of diseased artery, for example, 
in macrophage-rich regions of atheroma.25 Furthermore, 
5% O
2
 is not true hypoxia and is, in fact, a normal oxygen 
concentration for many tissues. In this present study, we 
demonstrated a priming effect of profound hypoxia on the 
reparative action of EPO and pHBSP. Hypoxia promotes a 
set of signaling pathways that directly affect vascular cell 
proliferation and survival, or act indirectly to influence 
the response to locally produced growth factors.26 These 
responses are largely mediated by the activation of the tran-
scriptional factor, HIF-1, which controls the transcription 
of DNA to mRNA of more than a hundred target genes.27 
There is increasing evidence that HIF-1 plays a critical role 
in mediating the protective effects of hypoxic episodes by 
inducing cytoprotective molecules such as EPO.28 In our 
experiments, we measured HIF-1α as a marker of cellular 
responses to hypoxia.
The expression of EPOR determines the responsiveness 
of cells to EPO.28 We have previously shown that at normal 
O
2
 tension (21%), BAECs express EPOR at low levels, lead-
ing to low EPO activity, and that at a lower O
2
 tension (5%), 
there is an increase in EPOR expression, priming endothelial 
cells to the reparative activity of EPO.29 This repair process 
appears to be due to the well-characterized ability of EPO and 
its analogs to promote cell proliferation and migration.26,30 We 
found in this study that these effects were also observed at 
1% O
2
. As shown by others earlier, these effects may involve 
activation of PI3K/AKT phosphorylation, JAK2/STAT5, 
RAS/MAPK, and the antiapoptotic pathway involving Bcl-2 
and Bcl-XL,28,31 but the proximal trigger for these changes 
has not been unequivocally identified.
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Figure 7 PTIO (150 µM) inhibits repair in a scratch assay model in BAECs under 
both normoxia and hypoxia both in untreated cells (*P,0.05) and in EPO/pHBSP-
treated cells (*P,0.05).
Note: Each data point represents the mean value ± SEM (n=3). Statistical analysis 
was carried out using one-way aNOVa followed by Bonferroni post-hoc test. 
Abbreviations: Baecs, bovine aortic endothelial cells; ePO, erythropoietin; 
pHBsP, pyroglutamate helix B surface peptide; PTiO, 2-phenyl-4,4,5,5-
tetramethylimidazoline-1-oxyl 3-oxide; seM, standard error of the mean.
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The eNOS-mediated production of NO is a key regulator 
of vascular tone and blood flow.32 It is also involved in regulat-
ing endothelial permeability, platelet aggregation, leukocyte 
adhesion, and cell migration.32,33 Recent studies have sug-
gested that eNOS has an essential role in the cytoprotective 
and tissue-protective effect of EPO.34,35 Wound repair in vivo 
is also modulated by NO, affecting several pathophysiological 
processes including inflammation, chemotaxis, antibacterial 
defenses, collagen production, and angiogenesis.36
Oxygen tension may influence NO signaling by 
affecting NOS-dependent NO production, a process that 
requires O
2
. At low O
2
 tension, eNOS expression and 
activity is thought to be reduced, and NO production by 
alternative, NOS-independent pathways, for example, the 
reduction of nitrite to NO, may occur.37,38 This notion is 
supported by the lack of l-NAME effect on the migra-
tion, proliferation, and wound closure of hypoxic cells 
compared to normoxic cells. In the present study, we found 
little evidence for the involvement of NOS-independent 
pathways in mediating the effects of EPO on BAEC pro-
liferation, migration, and apoptosis under hypoxic condi-
tions, since all of these reparative effects were reduced 
substantially by NOS inhibition. Therefore, under hypoxic 
conditions, it is possible that NO-mediated wound healing 
is decreased to a large degree by a combination of two 
effects, l-NAME inhibition of eNOS and the reduction of 
eNOS expression and activity by hypoxia. This does not 
rule out other, NOS-independent, pathways; however, our 
findings suggest that, at least in this experimental model, 
they may not play a major role.
Earlier experiments have shown that EPO stimulates NO 
production in endothelial cells and that this effect is more 
marked in hypoxia.39 This effect of EPO could occur through 
an upregulation of eNOS phosphorylation at Ser-1177, which 
activates the enzyme, and our current experiments show that 
EPO restores eNOS phosphorylation under hypoxic condi-
tions. The lower activity and expression of activated NOS in 
endothelial cells under hypoxic conditions could explain why 
wound healing is delayed in hypoxia. We further extend our 
earlier observations on the stimulation of NO production by 
EPO by demonstrating that the reparative effects of EPO and 
pHBSP are abrogated not only by NOS inhibition but also 
by the presence of an NO scavenger. Moreover, we showed 
for the first time that the extent of NO stimulation by EPO 
correlates with the magnitude of its biological effects under 
all experimental conditions, providing additional support 
for a crucial role of NO in mediating the action of EPO and 
its analogs.
We also studied the possible involvement of iNOS as 
a source of NO. As expected, in normoxic cells, we could 
only find a very faint band for iNOS by Western blot, but its 
expression was clearly increased under hypoxic conditions. 
This effect was partially inhibited when cells were treated 
with EPO. Due to the complexity of the system and possibil-
ity of multiple sources of NO production, the quantitative 
analysis of nitrite and nitrate was essential to determine the 
involvement of NO under different oxygen tensions.
Altogether, we found that hypoxia enhances the repara-
tive effect of EPO (and its analogs), and this may explain 
the protective effects observed when these molecules are 
adminis tered in several models of ischemic injury. Under-
standing the mechanisms responsible for these effects on 
the vascular endothelium could provide novel regenerative 
therapeutics in the treatment of cardiovascular disease, spe-
cifically in restenosis following angioplasty. Our findings 
strongly support the role of NO in mediating the reparative 
effects of EPO and its analogs under hypoxic conditions, 
corroborating and extending observations from other groups 
in different model systems.40
Conclusion
In this study, the reparative effects of EPO and its nonery-
thropoietic analog p-HBSP were assessed in cultured BAECs 
under hypoxic and normoxic conditions. We have shown 
that hypoxia primes the reparative cellular effects of EPO 
and p-HBSP and that these are largely mediated by eNOS 
activation and enhanced cellular NO production. Further 
work should be directed at disentangling the precise nature of 
this interaction and its possible relationship to cellular redox 
status and some of the signaling events downstream of the 
emerging EPO/EPOR/NO axis, underpinning its beneficial 
biological effects.
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Figure S1 Effect of different concentrations of (A) pHBSP (0–100 µM) and (B) l-NaMe (0–1,000 µM) on wound closure in BAECs under 21% or 1% O2.
Note: Each data point represents mean ± SEM (n=4). statistical analysis was carried out using one-way aNOVa followed by Bonferroni post-hoc test where *P,0.05, 
**P,0.01.
Abbreviations: Baecs, bovine aortic endothelial cells; l-NaMe, NG-nitro-l-arginine methyl ester; pHBsP, pyroglutamate helix B surface peptide; seM, standard error of 
the mean.
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Figure S2 iNOs expression increased under hypoxic conditions 
Notes: (A) Western blot analysis of BAECs cultured under 21% O2 and 1% O2 for 24 hours in the absence (−) and presence (+) of ePO, showing the expression of iNOs (130 
kDa). GAPDH (37 kDa) was used as loading control for the samples. (B) Densitometric quantification following normalization against gaPDH. each data point represents 
mean ± SEM of three independent experiments (n=3). Statistical analysis was carried out using t-test (*P,0.05).
Abbreviations: Baecs, bovine aortic endothelial cells; ePO, erythropoietin; iNOs, inducible nitric oxide synthase; seM, standard error of the mean.
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